Browse the evidence

Weight loss reduces the recurrence of symptomatic atrial fibrillation.

Weight management should be a focus in the treatment plan for patients with AF.

Oral semaglutide, 50 mg, led to a mean percentage change in body weight of -14.3% compared to -1.3% with placebo.

Oral semaglutide is effective for significant weight loss in this population.

84.3% of participants on semaglutide achieved a 5% or greater body weight reduction compared to 17.2% on placebo.

A high proportion of patients on semaglutide can expect significant weight loss.

R-ESG offered higher total body weight loss (TBWL%) than GLP1/GIP-RA at 3 months (11.2% vs. 4.3%, p < .001), 6 months (13.5% vs. 6.8%, p < .001), and 12 months (13.4% vs. 9.2%, p = .07).

Practitioners may consider R-ESG as a more effective option for weight loss in patients experiencing weight recidivism after sleeve gastrectomy.

GLP1/GIP-RA achieved significantly lower TBWL% in patients with prior SG compared to those with intact stomach at 3 months (4.3% vs. 5.7%, p = .02), 6 months (6.8% vs. 9.2%, p = .02), and 12 months (9.2% vs. 12.7%, p = .03).

Practitioners should be aware that GLP1/GIP-RA may be less effective for weight loss in patients with prior sleeve gastrectomy compared to those with intact stomachs.

Excess adiposity is associated with worse outcomes in breast cancer survivors.

Practitioners should consider addressing excess adiposity in breast cancer survivors to improve health outcomes.

Excess adiposity can be targeted to improve breast cancer outcomes.

Interventions aimed at reducing excess adiposity may enhance survivorship and quality of life for breast cancer survivors.

Novel incretin-based therapies have gained popularity due to their effectiveness in achieving substantial weight loss.

Healthcare providers should consider incretin-based therapies as effective options for weight management.

Tirzepatide-associated improvements in cardiometabolic risk factors are positively related to the degree of weight reduction.

Weight reduction through tirzepatide can lead to significant improvements in cardiometabolic health.

Improvements in triglycerides, HDL cholesterol, LDL cholesterol, and non-HDL cholesterol were primarily observed after weight reductions greater than 10%.

Targeting a weight reduction of over 10% may be necessary for significant improvements in lipid profiles.

The steepest improvements in cardiometabolic risk factors occurred between less than 5% and less than 20% weight reduction.

Practitioners should note that even modest weight loss can lead to significant health improvements, particularly within the 5-20% range.

GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIPRA) significantly reduce body weight and adiposity.

Practitioners can expect significant weight loss and reduction in adiposity with GLP-1RA and GLP-1/GIPRA therapies.

Moderate-to-vigorous physical activity (MVPA) is inversely associated with all-cause mortality in individuals with type 2 diabetes.

Encourage patients with type 2 diabetes to engage in regular MVPA to reduce mortality risk.

Consuming protein supplements with meals may more effectively promote weight control and reduce fat mass compared to consuming them between meals.

Practitioners should consider recommending protein supplements with meals for better fat loss outcomes.

A higher percentage of individuals consuming protein supplements between meals showed increases in body mass compared to those consuming with meals.

While body mass may increase with protein between meals, it is essential to consider overall body composition goals.

A higher percentage of individuals consuming protein supplements with meals showed an increase in the ratio of lean mass to fat mass over time compared to those consuming between meals.

Encouraging protein consumption with meals may enhance body composition improvements.

Correcting hormonal deficiencies may improve exercise capacity and reduce major cardiac events.

Clinicians should consider hormonal assessments in patients at risk of cardiovascular events.

Lifestyle modifications have shown to prevent the progression to type 2 diabetes mellitus.

Practitioners should emphasize lifestyle modifications for diabetes prevention.

Lorcaserin, phentermine with topiramate, bupropion with naltrexone, and liraglutide have proven effects on reducing weight in patients with type 2 diabetes and obesity.

Practitioners can consider these medications for weight management in diabetic patients.

Phentermine with topiramate is the most efficacious medication for weight loss among the studied antiobesity medications.

Phentermine with topiramate may be prioritized for weight loss in diabetic patients.

Patients in the clinical pharmacist cohort achieved a mean body weight reduction of 9.32% compared to 5.11% body weight reduction for patients in the primary care physician cohort.

Incorporating clinical pharmacists in weight management can lead to greater weight loss outcomes.

Pharmacists can effectively evaluate and monitor the use of GLP-1 therapy in weight management patients.

Utilizing pharmacists in weight management can enhance patient care and therapy outcomes.

Patients receiving email-based health coaching and Semaglutide therapy lost a mean weight of 9.52% over 5 months.

Email-based coaching combined with Semaglutide can be effective for weight loss in overweight and obese patients.

81.51% of the cohort lost a 'meaningful' amount of weight (5% or more).

A high percentage of participants achieved significant weight loss, indicating the program's effectiveness.